| Bioactivity | IDOR-1117-2520 is a potent and selective antagonist of CCR6. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC50 = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC50 = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 can be used for research of autoimmune diseases[1]. |
| CAS | 2737274-49-4 |
| Formula | C25H32N4O3 |
| Molar Mass | 436.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Meyer EA, et al. Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases. J Med Chem. 2024 May 10. |
IDOR-1117-2520
CAS: 2737274-49-4 F: C25H32N4O3 W: 436.55
IDOR-1117-2520 is a potent and selective antagonist of CCR6. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.